GTS Securities LLC Sells 36,238 Shares of Qiagen (NYSE:QGEN)

GTS Securities LLC decreased its position in Qiagen (NYSE:QGEN - Free Report) by 66.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,448 shares of the company's stock after selling 36,238 shares during the quarter. GTS Securities LLC's holdings in Qiagen were worth $821,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of QGEN. Groupama Asset Managment grew its stake in shares of Qiagen by 8,074.0% in the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after acquiring an additional 32,216,761 shares during the last quarter. Norges Bank acquired a new stake in shares of Qiagen in the fourth quarter worth $181,529,000. Massachusetts Financial Services Co. MA grew its stake in shares of Qiagen by 9.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after acquiring an additional 2,202,040 shares during the last quarter. Caisse Des Depots ET Consignations acquired a new stake in shares of Qiagen in the fourth quarter worth $53,991,000. Finally, Barclays PLC grew its stake in shares of Qiagen by 170.6% in the third quarter. Barclays PLC now owns 1,849,004 shares of the company's stock worth $84,259,000 after acquiring an additional 1,165,594 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Shares of Qiagen stock traded down $0.09 during trading on Friday, reaching $44.91. The company's stock had a trading volume of 902,580 shares, compared to its average volume of 1,158,915. The stock has a 50-day moving average price of $41.59 and a two-hundred day moving average price of $41.85. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. Qiagen has a one year low of $37.63 and a one year high of $49.30. The stock has a market capitalization of $9.98 billion, a P/E ratio of 125.15, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The business had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same period in the previous year, the business posted $0.44 earnings per share. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

QGEN has been the topic of a number of recent research reports. Redburn Atlantic downgraded shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Wall Street Zen upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Baird R W downgraded shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Robert W. Baird boosted their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, UBS Group reduced their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.